Novartis stock price hit $100.05 briefly today, a psychological level for many traders. The move was supported by positive trial results in its oncology segment, a key growth driver in the pharmaceutical sector. Novartis' newer approvals should also help it move past this issue. Vanrafia, which treats proteinuria (excess protein in urine) in patients with IgA nephropathy, earned the green light in April. The company has a deep pipeline, with dozens of products that should lead to plenty of additional approvals and label expansions. Is PG&E an AI Power Play? Why Options Traders Are Betting Big Novartis stock price dips slightly to $98.95 as traders reassess valuation metrics. Nonetheless, buy-side desks maintain overweight ratings given the company’s consistent free cash flow generation.